TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10806607

Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Metoprolol (50 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg) and Metoprolol (50 mg) together
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 10180860

Group type: EXPERIMENTAL
Intervention: Vitamin D injection
Number of subjects: 100000

Group type: COMPARATOR
Intervention: Calcitonin
Number of subjects: 100000
Study: 1710921

Group type: EXPERIMENTAL
Intervention: MOPP-ABVD alternating regimen (monthly alternating one cycle of MOPP and one cycle of ABVD)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: MOPP-ABVD hybrid regimen (one half cycle of MOPP alternated with one half cycle of ABVD within a one-month period)
Number of subjects: 300
Study: 6128673

Group type: EXPERIMENTAL
Intervention: Systematic desensitization
Number of subjects: 60

Group type: COMPARATOR
Intervention: Counseling
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 60
Study: 31596119

Group type: EXPERIMENTAL
Intervention: Group 1 standardisation
Number of subjects: 382

Group type: COMPARATOR
Intervention: Group 2 validation
Number of subjects: 382
Study: 27696324

Group type: EXPERIMENTAL
Intervention: Aggressive response generation
Number of subjects: 731
Study: 25510926

Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy (CET)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 31
Study: 23022092

Group type: EXPERIMENTAL
Intervention: Instruction-only group (multimedia presentation)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Feedback group (multimedia presentation and real-time visual feedback)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 27
Study: 22137863

Group type: EXPERIMENTAL
Intervention: Water with TGHP (iodine-based tetraglycine hydroperiodide)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Water with CD (chlorine dioxide)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Water with TGHP plus ascorbic acid
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Water alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Water with CD plus ascorbic acid
Number of subjects: 60
Study: 19638454

Group type: EXPERIMENTAL
Intervention: MTX monotherapy
Number of subjects: 230

Group type: COMPARATOR
Intervention: MTX and SSZ combination therapy
Number of subjects: 230

Group type: COMPARATOR
Intervention: MTX-SSZ group
Number of subjects: 230
Study: 16990992

Group type: EXPERIMENTAL
Intervention: recombinant human MBL (rhMBL) 0.01, 0.05, 0.1, and 0.5 mg/kg single intravenous infusions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: recombinant human MBL (rhMBL) 0.1 or 0.3 mg/kg repeated intravenous infusions at 3-day intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: recombinant human MBL (rhMBL) 0.5 mg/kg single intravenous infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: recombinant human MBL (rhMBL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 15502290

Group type: EXPERIMENTAL
Intervention: Job specific training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Basic body mechanic training (BBMT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 11046206

Group type: EXPERIMENTAL
Intervention: Inhaled albuterol (4 puffs, 15-20 min before intubation)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg, 3 min before intubation)
Number of subjects: 60
Study: 8375519

Group type: EXPERIMENTAL
Intervention: Intramuscular hCG (10,000 IU)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous hCG (500 IU)
Number of subjects: 30
Study: 3018822

Group type: EXPERIMENTAL
Intervention: Physostigmine (22 micrograms/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Neostigmine (11 micrograms/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Scopolamine (0.5 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Methscopolamine (0.75 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Physostigmine (22 micrograms/kg) with scopolamine
Number of subjects: 10
Study: 30107400

Group type: EXPERIMENTAL
Intervention: Innovative trial designs and analytical methods for randomized clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacokinetic and pharmacodynamic modeling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensitive primary end points
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hierarchical nested-trial designs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian methods and/or platform trials
Number of subjects: 0
Study: 25854535

Group type: COMPARATOR
Intervention: Exercise-based PE
Number of subjects: 767

Group type: COMPARATOR
Intervention: Games-based PE
Number of subjects: 767
Study: 24557728

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/r)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 224
Study: 22999808

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide/salbutamol sulfate (500 μg/2.5 mg) combination
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (NaCl)
Number of subjects: 37
Study: 20691306

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EESs)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PESs)
Number of subjects: 109
Study: 18294310

Group type: EXPERIMENTAL
Intervention: Oral alitretinoin 10 mg once daily for up to 24 weeks
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: Oral alitretinoin 30 mg once daily for up to 24 weeks
Number of subjects: 1032

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1032
Study: 15783281

Group type: EXPERIMENTAL
Intervention: Motivationally based intervention (MBI)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Assessment-only control (AC)
Number of subjects: 73
Study: 12637478

Group type: EXPERIMENTAL
Intervention: 4 cycles of BEP chemotherapy (bleomycin, etoposide, cisplatin) over 5 days
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: 3 cycles of BEP chemotherapy (bleomycin, etoposide, cisplatin) over 3 days
Number of subjects: 666
Study: 10471647

Group type: EXPERIMENTAL
Intervention: PRO-Trac II ELISA
Number of subjects: 0
Study: 8611382

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (600 mg m‐2) administered every 3 weeks for three courses with prednisone and interferon‐alpha2b
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Epirubicin (70 mg m‐2) administered every 3 weeks for three courses with prednisone and interferon‐alpha2b
Number of subjects: 83
Study: 1416333

Group type: EXPERIMENTAL
Intervention: Pressurized saline canister (220 mL saline at 8 psi)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Syringe irrigation (250 mL saline)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Pressurized saline canister
Number of subjects: 550

Group type: COMPARATOR
Intervention: Syringe irrigation
Number of subjects: 550
Study: 4074604

Group type: EXPERIMENTAL
Intervention: Reproterol 1 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Reproterol 8 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Reproterol (various doses)
Number of subjects: 14
Study: 29602338

Group type: EXPERIMENTAL
Intervention: Supplementary use of an intraoral vibrational device (AcceleDent; 20 minutes/day) (n=29)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Identical nonfunctional (sham) device (n=25)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Fixed-appliance only (n=27)
Number of subjects: 81
Study: 27990219

Group type: EXPERIMENTAL
Intervention: Walking with Nordic poles
Number of subjects: 20

Group type: COMPARATOR
Intervention: Walking without Nordic poles
Number of subjects: 20
Study: 24131826

Group type: EXPERIMENTAL
Intervention: Prebiotics (galacto‐oligosaccharide and polydextrose mixture, 1:1)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus GG, ATCC 53103)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Prebiotics
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 94
Study: 22407240

Group type: EXPERIMENTAL
Intervention: OG tube-guided technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard digital technique
Number of subjects: 60
Study: 20597833

Group type: EXPERIMENTAL
Intervention: Mobile telemonitoring
Number of subjects: 137

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Mobile telemonitoring (specifically for patients of African origin)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Mobile telemonitoring (for patients achieving systolic blood pressure <120 mm Hg)
Number of subjects: 137
Study: 18703604

Group type: EXPERIMENTAL
Intervention: Enhanced (18)F-FDG PET/CT
Number of subjects: 50

Group type: COMPARATOR
Intervention: PET alone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Unenhanced PET/CT
Number of subjects: 50
Study: 15781815

Group type: EXPERIMENTAL
Intervention: Interferon beta-1b
Number of subjects: 708

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 708
Study: 12492903

Group type: EXPERIMENTAL
Intervention: 0.0625% P‐113 gel
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 0.125% P‐113 gel
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 0.375% P‐113 gel
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: P‐113 treatment groups
Number of subjects: 106
Study: 10357420

Group type: EXPERIMENTAL
Intervention: Cystectomy performed within 3 months after initial diagnosis
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Immediate cystectomy
Number of subjects: 138

Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 138
Study: 7860449

Group type: EXPERIMENTAL
Intervention: Child Behavior Problem Questionnaire (CBPQ)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Maternal psychiatric symptoms
Number of subjects: 611
Study: 1632542

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with epinephrine (5 micrograms/mL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with epinephrine (5 micrograms/mL)
Number of subjects: 20
Study: 6092287

Group type: EXPERIMENTAL
Intervention: Activated charcoal, 50 g given within 5 min of sotalol hydrochloride (160 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Activated charcoal, repeated doses of 50 g followed by 12.5 g at 6 h intervals
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control phase (no intervention)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Acidification or alkalinization of urine for 3 days
Number of subjects: 7
Study: 31631796

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography
Number of subjects: 6985

Group type: EXPERIMENTAL
Intervention: CT or MR angiogram
Number of subjects: 6985

Group type: COMPARATOR
Intervention: Diagnostic testing
Number of subjects: 6985
Study: 30882914

Group type: EXPERIMENTAL
Intervention: 400 or 800 mg UDCA on day 1, followed by 200 mg UDCA twice daily for 2 weeks
Number of subjects: 32
Study: 30121146

Group type: EXPERIMENTAL
Intervention: HIVIS-DNA and MVA-CMDR-HIV alone (n=12)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: HIVIS-DNA and MVA-CMDR combined with protein CN54rgp140 (n=13)
Number of subjects: 25
Study: 26875065

Group type: EXPERIMENTAL
Intervention: Intra-articular injection (IA group)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Subacromial injection (SA group)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Combined IA and subacromial injections (IA+SA group)
Number of subjects: 126
Study: 24390400

Group type: EXPERIMENTAL
Intervention: Intracameral preservative-free lidocaine 1%
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intracameral injection of balanced salt solution (sham injection)
Number of subjects: 100
Study: 22112807

Group type: EXPERIMENTAL
Intervention: Once-daily (OD) hydrocortisone dual-release tablet
Number of subjects: 64
Study: 20715787

Group type: EXPERIMENTAL
Intervention: Three novel nonsteroidal glucocorticoid receptor agonists applied at low dose in ethanol solution.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MALDI MSI and LESA with nESI‐MS techniques used for analysis.
Number of subjects: 0
Study: 17697555

Group type: EXPERIMENTAL
Intervention: GEMOX regimen (gemcitabine of fixed-dose rate infusion plus oxaliplatin)
Number of subjects: 869

Group type: COMPARATOR
Intervention: GEM alone (control)
Number of subjects: 869
Study: 16270720

Group type: EXPERIMENTAL
Intervention: Cetirizine, 10 mg
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Fexofenadine, 180 mg
Number of subjects: 599

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Cetirizine vs Fexofenadine
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 599
Study: 12147372

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg daily)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 168
Study: 9914569

Group type: EXPERIMENTAL
Intervention: leuprolide acetate depot
Number of subjects: 51

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 51
Study: 7752652

Group type: EXPERIMENTAL
Intervention: (R)-propranolol (2, 10, and 50 micrograms/min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: (S)-propranolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: (R)-atenolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: (S)-atenolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: (R)-propranolol
Number of subjects: 12
Study: 2270767

Group type: EXPERIMENTAL
Intervention: 150 mg fluconazole (oral)
Number of subjects: 99

Group type: COMPARATOR
Intervention: 1200 mg miconazole (intravaginal)
Number of subjects: 99
Study: 7230336

Group type: EXPERIMENTAL
Intervention: estramustine phosphate
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: estramustine phosphate plus vincristine
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: vincristine
Number of subjects: 121

Group type: COMPARATOR
Intervention: estramustine phosphate, vincristine, estramustine phosphate plus vincristine
Number of subjects: 121
Study: 30149982

Group type: EXPERIMENTAL
Intervention: Simulation-based learning
Number of subjects: 28

Group type: COMPARATOR
Intervention: Problem-based learning (PBL)
Number of subjects: 28
Study: 28392807

Group type: EXPERIMENTAL
Intervention: setipiprant 1000 mg b.i.d. (Phase 2 trial)
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: setipiprant 1000 mg b.i.d. (Phase 3 trial)
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: setipiprant 1000 mg b.i.d. (both trials)
Number of subjects: 1209

Group type: COMPARATOR
Intervention: placebo (Phase 2 trial)
Number of subjects: 1209

Group type: COMPARATOR
Intervention: cetirizine (active control in both trials)
Number of subjects: 1209
Study: 26611245

Group type: EXPERIMENTAL
Intervention: Oxymetazoline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: N2O
Number of subjects: 20
Study: 24650461

Group type: EXPERIMENTAL
Intervention: Surgical interventions (including gastroschisis closure and ductus arteriosus ligation)
Number of subjects: 724
Study: 22468715

Group type: EXPERIMENTAL
Intervention: The Great Escape computer game intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified what intervention was used)
Number of subjects: 0
Study: 21050201

Group type: EXPERIMENTAL
Intervention: Coping and support group interventions
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 108
Study: 17458505

Group type: EXPERIMENTAL
Intervention: AZD2171 at 2.5 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: AZD2171 at 20 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: AZD2171 at 30 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: AZD2171 (various doses)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: AZD2171
Number of subjects: 26
Study: 15138906

Group type: EXPERIMENTAL
Intervention: 20 mg ropivacaine plus 0.1 mg morphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 15 mg bupivacaine plus 0.1 mg morphine
Number of subjects: 60
Study: 12011536

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam 4.5 g q6h
Number of subjects: 12

Group type: COMPARATOR
Intervention: Piperacillin/tazobactam 3.375 g q4h
Number of subjects: 12
Study: 9657626

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham smoking
Number of subjects: 31
Study: 7657193

Group type: EXPERIMENTAL
Intervention: Piracetam/HAES 6%
Number of subjects: 39

Group type: COMPARATOR
Intervention: Naftidrofuryl/HAES 6%
Number of subjects: 39
Study: 2683900

Group type: EXPERIMENTAL
Intervention: Dipstick leukocyte esterase test (LET)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Routine cell count determinations and cultures
Number of subjects: 800
Study: 773497

Group type: EXPERIMENTAL
Intervention: Radical regimen (simple mastectomy and radiotherapy)
Number of subjects: 2268

Group type: COMPARATOR
Intervention: Conservative policy (simple mastectomy alone)
Number of subjects: 2268
Study: 31362081

Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33 °C
Number of subjects: 151

Group type: COMPARATOR
Intervention: Targeted temperature management at 36 °C
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Higher heart rate during TTM
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Lower stroke volume during TTM
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Increasing lactate during TTM
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Lower mean arterial pressure during TTM
Number of subjects: 151
Study: 28129749

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg (switched to 0.5 mg)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg (continuous treatment)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Fingolimod (both dosages)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo (initial group switched to fingolimod)
Number of subjects: 143
Study: 26545513

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention
Number of subjects: 42

Group type: COMPARATOR
Intervention: Traditional Treatment
Number of subjects: 42
Study: 23870217

Group type: EXPERIMENTAL
Intervention: Surgicel (oxidized cellulose patch)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Conventional procedures (ligatures and bipolar electrocautery)
Number of subjects: 190
Study: 22232914

Group type: EXPERIMENTAL
Intervention: cycloferon liniment
Number of subjects: 80
Study: 19934870

Group type: EXPERIMENTAL
Intervention: Standard polyvinyl chloride tracheal tubes
Number of subjects: 347

Group type: COMPARATOR
Intervention: Standard wire‐reinforced tracheal tubes
Number of subjects: 347

Group type: COMPARATOR
Intervention: Silicone wire‐reinforced tubes
Number of subjects: 347
Study: 16367899

Group type: EXPERIMENTAL
Intervention: Contralateral acoustic stimulation (CAS) in myasthenic patients
Number of subjects: 16

Group type: COMPARATOR
Intervention: Contralateral acoustic stimulation (CAS) in control group
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Contralateral acoustic stimulation (CAS) in myasthenic patients utilizing masking effect
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Assessment after 2 months in myasthenic patients
Number of subjects: 16
Study: 15192621

Group type: EXPERIMENTAL
Intervention: High-dose levothyroxine (12.0 microg/kg per day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (40 children)
Number of subjects: 18
Study: 11251517

Group type: EXPERIMENTAL
Intervention: Anderson-Hynes pyeloplasty
Number of subjects: 41
Study: 9333592

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 4,000 mg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Magnesium glutamate 2 x 1,000 mg intravenously
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Magnesium (2 x 9 mmol)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Magnesium injection
Number of subjects: 43
Study: 8507963

Group type: EXPERIMENTAL
Intervention: Alternative surgical technique (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional surgical technique (Group B)
Number of subjects: 40
Study: 3304370

Group type: EXPERIMENTAL
Intervention: DDD pacing
Number of subjects: 15

Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 15
Study: 29386302

Group type: EXPERIMENTAL
Intervention: BIS-guided fluid management
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (clinical information alone)
Number of subjects: 137
Study: 27898068

Group type: EXPERIMENTAL
Intervention: 8-week yoga intervention
Number of subjects: 28

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 28
Study: 24722235

Group type: EXPERIMENTAL
Intervention: Probiotic VSL#3 strains (D‐VSL#3, n=10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination therapy with prednisone and metronidazole (D‐CT, n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy dogs and archived intestinal tissues)
Number of subjects: 20
Study: 23560384

Group type: EXPERIMENTAL
Intervention: Positive Thoughts and Actions (PTA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Individual Support Program (ISP)
Number of subjects: 120
Study: 20004480

Group type: EXPERIMENTAL
Intervention: Mood stabilizers
Number of subjects: 144

Group type: COMPARATOR
Intervention: Healthy unrelated controls
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Genotypes in manic patients
Number of subjects: 144
Study: 18991138

Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 1
Study: 16682585

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone before PRP
Number of subjects: 9

Group type: COMPARATOR
Intervention: PRP alone (control)
Number of subjects: 9
Study: 15474871

Group type: EXPERIMENTAL
Intervention: Diet-plus-exercise (DEX)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Exercise-only (EX)
Number of subjects: 90